%0 Journal Article
%T Therapy with botulinum neurotoxin for Parkinson's disease.
%A Jost WH
%A Berberovic E
%J J Neural Transm (Vienna)
%V 0
%N 0
%D 2024 Jul 25
%M 39052120
%F 3.85
%R 10.1007/s00702-024-02805-y
%X Botulinum neurotoxin (BoNT) has been in use since the 1970's. Its effect is reached mainly by inhibiting the release of acetylcholine in the synaptic gap of motor neurons or at the motor end plate and the parasympathetic ganglia. In the case of Parkinson's disease, it is used to treat several motor and non-motor symptoms. Within recent years increasingly numerous possible fields of application of BoNT have been found for the treatment of Parkinson's disease, and for some specific symptoms it has in fact become the therapy of choice, while for others it is but one of the therapeutic options that come into consideration when others are not sufficiently effective. In the following, we intend to outline the indications, the possible side effects and also the approvals for therapies with botulinum toxin in the primary and secondary symptoms of Parkinson's disease.